[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TW200613006A - Rebamipide preparation for rectal administration to be prepared before using - Google Patents

Rebamipide preparation for rectal administration to be prepared before using

Info

Publication number
TW200613006A
TW200613006A TW094130255A TW94130255A TW200613006A TW 200613006 A TW200613006 A TW 200613006A TW 094130255 A TW094130255 A TW 094130255A TW 94130255 A TW94130255 A TW 94130255A TW 200613006 A TW200613006 A TW 200613006A
Authority
TW
Taiwan
Prior art keywords
preparation
rebamipide
rectal administration
prepared before
solid particle
Prior art date
Application number
TW094130255A
Other languages
Chinese (zh)
Inventor
Hirofumi Doi
Shun-Ichiro Sumida
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of TW200613006A publication Critical patent/TW200613006A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Rebamipide preparation for rectal administration to be prepared before using, which is a solid particle preparation comprising rebamipide and carmellose sodium and having excellent dispersibility in an aqueous vehicle, and can be administered rectally in the form of enema dispersion preparation by dispersing the solid particle preparation in an aqueous vehicle when used. The present rebamipide preparation is in a solid particle form such as a powder or pulverized powder form or a fine granule or granule form, and hence, it has excellent storage stability.
TW094130255A 2004-09-10 2005-09-05 Rebamipide preparation for rectal administration to be prepared before using TW200613006A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004263638 2004-09-10

Publications (1)

Publication Number Publication Date
TW200613006A true TW200613006A (en) 2006-05-01

Family

ID=36036545

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094130255A TW200613006A (en) 2004-09-10 2005-09-05 Rebamipide preparation for rectal administration to be prepared before using

Country Status (2)

Country Link
TW (1) TW200613006A (en)
WO (1) WO2006028270A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (en) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
CN105012267A (en) * 2015-08-19 2015-11-04 海南科进生物制药有限公司 Rebamipide tablet and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06157355A (en) * 1992-11-13 1994-06-03 Dai Ichi Seiyaku Co Ltd Granular preparation for mri
JP3927253B2 (en) * 1995-02-02 2007-06-06 中外製薬株式会社 Sucralfate formulation

Also Published As

Publication number Publication date
WO2006028270A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
ES2191616T3 (en) PULVERIZABLE POWDER OF FLUOROPOLIMEROS NON FIBRILABLE.
MX2011012196A (en) Compositions and methods for drug delivery.
AP2003002819A0 (en) Pharmaceutical compositions comprising amlodipine maleate
WO2007142888A3 (en) Concentrated fluoropolymer dispersions stabilized with anionic polyelectrolyte dispersing agents
MX336930B (en) Ganaxolone formulations and methods for the making and use thereof.
WO2007053408A3 (en) Luminescent compositions, methods for making luminescent compositions and inks incorporating the same
WO2007116954A3 (en) Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
WO2014022368A3 (en) Anti-reflective hard coat and anti-reflective article
IN2015DN00888A (en)
WO2014066468A8 (en) Stable, low viscosity antibody formulation
BR112015031906A2 (en) electrode material and its use in lithium ion batteries
WO2005104712A3 (en) Dpi formulation containing sulfoalkyl ether cyclodextrin
WO2009060803A1 (en) Copper fine particle, method for producing the same, and copper fine particle dispersion
WO2008011641A3 (en) A method of agglomeration
WO2008149788A1 (en) Solid dialysis preparation
DE602005025083D1 (en)
WO2009077412A3 (en) Aqueous slurry comprising inorganic oxygen-containing particulates
WO2011134962A3 (en) Orally disintegrating tablet containing acarbose
TW200613006A (en) Rebamipide preparation for rectal administration to be prepared before using
WO2011090724A3 (en) Gastroretentive solid oral dosage forms with lipid-based low-density excipient
BRPI0516563A (en) tantalum powder for the production of solid electrolytic capacitors
WO2007048820A3 (en) Micronised azodicarbonamide, the preparation and use thereof
MY121175A (en) Ciclesonide-containing aqueous pharmaceutical composition
JP2013520393A5 (en)
TW200730888A (en) Coloring composition for use in color filter and color filter